s-1743 and Pancreatitis

s-1743 has been researched along with Pancreatitis* in 2 studies

Trials

2 trial(s) available for s-1743 and Pancreatitis

Article	Year
The impacts of acid suppression on duodenal microbiota during the early phase of severe acute pancreatitis. Scientific reports, 2020, 11-18, Volume: 10, Issue:1 Duodenal dysbiosis may be potential infection risks in patients with severe acute pancreatitis (SAP). Acid-suppression drugs (ACDs) are widely used in SAP patients in Asian countries. However, the impact of ACDs on duodenal microbiota during the early phase of SAP is still unknown. This randomized controlled clinical trial evaluated the impacts of esomeprazole (Eso), one of ACDs on duodenal microbiota during the first week of SAP with duodenal aspirates culture and 16sRNA Illumina sequencing analysis. 66 patients were randomized as 1:1 ratio into Eso group (Eso 40 mg/day) and Eso-N group (no Eso). The occurrence of duodenal bacterial overgrowth (DBO) was significantly higher in Eso group (about 85%) than that in Eso-N group (about 42%). The duodenal microbiota of the SAP patients shifted away from that of the normal control. There were differences between the Eso-N and Eso groups including enriched abundances of the class Negativicutes, order Selenomonadales and genus Veillonella. Acid suppression significantly increased incidence of Candida oesophagitis (CE) by 8-folds but did not increase other infectious events. In conclusion, acid suppression greatly increased the occurrence of DBO, duodenal dysbiosis and CE during the first week of SAP. Restrictive use of acid-suppressing medications might be helpful to reduce CE and potential risk of pancreatic infection in SAP patients.Trial registration: Chictr.org, ChiCTR-IPR-16008301, Registered April 18 2016, http://www.chictr.org.cn/showproj.aspx?proj=14089 . Topics: Acids; Adolescent; Adult; Aged; Anti-Ulcer Agents; Duodenum; Dysbiosis; Esomeprazole; Female; Humans; Male; Microbiota; Middle Aged; Pancreatitis; Young Adult	2020
[Effect of Proton Pump Inhibitors on Severe Acute Pancreatitis--a Prospective Randomized Trial]. Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2017, Volume: 48, Issue:6 To evaluate the effect of proton pump inhibitors (PPIs) therapy on severe acute pancreatitis (SAP) patients.. No significant difference was found in CRP,IL-6,IL-8,TNF-α and PCT between the two groups (. PPIs therapy did not show benefit on alleviating systemic inflammatory response and clinical scores in SAP patients,and didn't improve the prevention of peptic ulcer and gastrointestinal hemorrhage. Topics: Acute Disease; C-Reactive Protein; Calcitonin; Esomeprazole; Humans; Interleukin-6; Interleukin-8; Pancreatitis; Prospective Studies; Proton Pump Inhibitors; Tumor Necrosis Factor-alpha	2017

Article

Year

The impacts of acid suppression on duodenal microbiota during the early phase of severe acute pancreatitis.

Scientific reports, 2020, 11-18, Volume: 10, Issue:1

Duodenal dysbiosis may be potential infection risks in patients with severe acute pancreatitis (SAP). Acid-suppression drugs (ACDs) are widely used in SAP patients in Asian countries. However, the impact of ACDs on duodenal microbiota during the early phase of SAP is still unknown. This randomized controlled clinical trial evaluated the impacts of esomeprazole (Eso), one of ACDs on duodenal microbiota during the first week of SAP with duodenal aspirates culture and 16sRNA Illumina sequencing analysis. 66 patients were randomized as 1:1 ratio into Eso group (Eso 40 mg/day) and Eso-N group (no Eso). The occurrence of duodenal bacterial overgrowth (DBO) was significantly higher in Eso group (about 85%) than that in Eso-N group (about 42%). The duodenal microbiota of the SAP patients shifted away from that of the normal control. There were differences between the Eso-N and Eso groups including enriched abundances of the class Negativicutes, order Selenomonadales and genus Veillonella. Acid suppression significantly increased incidence of Candida oesophagitis (CE) by 8-folds but did not increase other infectious events. In conclusion, acid suppression greatly increased the occurrence of DBO, duodenal dysbiosis and CE during the first week of SAP. Restrictive use of acid-suppressing medications might be helpful to reduce CE and potential risk of pancreatic infection in SAP patients.Trial registration: Chictr.org, ChiCTR-IPR-16008301, Registered April 18 2016, http://www.chictr.org.cn/showproj.aspx?proj=14089 .

Topics: Acids; Adolescent; Adult; Aged; Anti-Ulcer Agents; Duodenum; Dysbiosis; Esomeprazole; Female; Humans; Male; Microbiota; Middle Aged; Pancreatitis; Young Adult

2020

[Effect of Proton Pump Inhibitors on Severe Acute Pancreatitis--a Prospective Randomized Trial].

Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2017, Volume: 48, Issue:6

To evaluate the effect of proton pump inhibitors (PPIs) therapy on severe acute pancreatitis (SAP) patients.. No significant difference was found in CRP,IL-6,IL-8,TNF-α and PCT between the two groups (. PPIs therapy did not show benefit on alleviating systemic inflammatory response and clinical scores in SAP patients,and didn't improve the prevention of peptic ulcer and gastrointestinal hemorrhage.

Topics: Acute Disease; C-Reactive Protein; Calcitonin; Esomeprazole; Humans; Interleukin-6; Interleukin-8; Pancreatitis; Prospective Studies; Proton Pump Inhibitors; Tumor Necrosis Factor-alpha

2017